Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $15.78M rose 17.1% year over year, behind the +28.2% change in trailing-twelve-month research & development. Sequentially, it fell 6.2% from the prior quarter. Over 3 fiscal years it compounded at +38.4% a year.

Context

  • Research & development amounted to 173.8% of revenue in FY2025, down 1448.8 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +17.1% toward the trailing-twelve-month pace of +28.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.78M-6.2% QoQ
Last fiscal yearDec 2025
$58.19M+35.9% YoY
LTMMar 2026
$60.48M+28.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.1%——
1 year+35.9%——
3-year CAGR+38.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
58.19M USD
Year-over-year change
+35.9%
4-year CAGR
+45.8%

Research & Development vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.2% is the 4th highest of 11, against a peer median of -14.4%.
  • Research & development amounts to 184.8% of revenue for OBIO, versus a peer median of 696.9%.
OBIO Competitors
Research & Development for OBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M USD-28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M USD-20.8%-13.4%131.9%
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M USD-33.8%+0.5%473.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M USD+21.5%-5.1%550.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M USD-24.6%-10.1%27721.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M USD+28.2%+38.4%184.8%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M USD-50.0%-40.2%104.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M USD+41.8%+36.4%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M USD+72.6%+29.4%—
Peer median (excluding OBIO) —-14.4%+5.3%696.9%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.